Literature DB >> 12490775

Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan.

Chia-Yih Liu1, Nan-Ying Chiu, Ching-Kuan Wu, Lo-Ming Yuan, Mei-Chun Hsiao, Oscar Liao.   

Abstract

Risperidone and olanzapine-administration data were collected for schizophrenia patients treated at four Taiwanese medical centres. Only stable patients maintained on a medication at a dose that had remained unchanged for more than 1 month were included in the analysis. Of the 268 cases, 175 were treated with risperidone and 93 with olanzapine at mean daily doses of 3.56 +/- 1.54 mg and 12.21 +/- 4.99 mg, respectively. The majority of the risperidone-treated patients (73.2%) received 2-4 mg per day, with another 19.0% receiving 5-6 mg. A daily dose of 10-20 mg was received by 82.9% of the olanzapine group. Although the mean daily doses for both drugs were slightly higher for inpatients than outpatients, statistical significance was not achieved. Further, no gender or age-group dose differences were demonstrated for either drug.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12490775     DOI: 10.1097/00004850-200301000-00008

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  1 in total

Review 1.  Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.

Authors:  William A Hargreaves; P Joseph Gibson; Joseph P Gibson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.